SCODiA Report by MLBI Lab

Single-Cell Transcriptomic Analysis Reveals Condition-Specific Cellular Dysregulation and Intercellular Communication Shifts in Familial and Sporadic Alzheimer's Disease Brains

This report details a single-cell RNA-seq analysis of human brain tissue, comparing control, familial (E280A), and sporadic Alzheimer's Disease (AD) conditions. We observe significant shifts in cell type proportions, particularly neuronal loss and reactive gliosis, with microglial populations polarizing towards M2-like states in AD. Intercellular communication is profoundly altered, impacting synaptic function, lipid metabolism, and neuroinflammation. Key brain cell types—neurons, microglia, and astrocytes—exhibit distinct condition-specific surfaceome markers and pathway dysregulations, offering insights into disease mechanisms unique to or shared between AD subtypes.

Contents

0. Dataset overview
1. Major Cell Type Score Visualization on UMAP
2. Marker Gene Expression Across Brain Cell Subtypes
3. Minor Cell Type Population Analysis Across Alzheimer's Disease Conditions
4. Microglial Subpopulation Shifts in Alzheimer's Disease
5. Microglial Subset Population Shifts in Alzheimer's Disease Conditions
6. Cell-Cell Interaction Patterns in Alzheimer's Disease Conditions
7. Condition-Specific Cell-Cell Interaction Patterns in Alzheimer's Disease
8. Neuron Surfaceome Marker Expression Across Alzheimer's Disease Conditions
9. Microglial Condition-Specific Surfaceome Markers in Alzheimer's Disease
10. Astrocyte Surfaceome Marker Expression Across Alzheimer's Disease Conditions
11. Gene Ontology (GSA) Analysis of Neuronal Pathways in Alzheimer's Disease Conditions
12. Gene Set Enrichment Analysis of Alzheimer's Disease Conditions Across Brain Cell Types
13. Discussion
14. Query List

0. Dataset overview

Dataset Summary

• Dimensions: This AnnData object contains data for 43,743 cells and 26,318 genes.
• Species and Tissue: The data is from human brain tissue.
• Metadata (obs columns): Key metadata columns include patient identifiers and clinical scores (e.g., Diagnosis, Patient, Sex, AAO, AAD, Post.mortem.time, NIA.A.A.SCORE, NIA.A.B.SCORE, NIA.A.C.SCORE, BRAAK, CERAD, NIA.AA), experimental conditions (e.g., condition, sample, orig.ident), and comprehensive cell type annotations at major, minor, and subset levels.
• Conditions: The dataset includes samples from three conditions: 'E280A', 'Control', and 'Sporadic'.

Cell Type Hierarchies:

• Major: Neuron, Oligodendrocyte, Astrocyte, Microglia, Endothelial cell, Stromal cell.
• Minor: Neuron, Oligodendrocyte progenitor cell, Astrocyte, Oligodendrocyte, Microglia, Endothelial cell, Smooth muscle cell, Fibroblast.
• Subset: Further detailed types like various neuronal subtypes, oligodendrocyte stages, and microglia activation states.

• CNV Estimates: Copy number variation estimates are not available for this dataset.
• Tumor Identification: Tumor identification was not requested for this dataset.
• Reference Condition: 'Control' is designated as the reference condition for comparative analyses such as DEG_vs_ref, GSEA_vs_ref, and GSA_vs_ref_up.

Precomputed Results Overview

The AnnData object is preloaded with several key analysis results:

• Cell-Cell Interaction (CCI): Results are available per condition (uns['CCI']) and per sample (uns['CCI_sample']).
• Differential Expression Genes (DEG): Precomputed results compare conditions against each other (uns['DEG']) or against the 'Control' reference condition (uns['DEG_vs_ref']) for various celltype_minor groups.
• Gene Set Enrichment Analysis (GSEA): GSEA results are available comparing conditions within each celltype_minor (uns['GSEA']) or against the 'Control' reference (uns['GSEA_vs_ref']).
• Gene Ontology (GO/GSA): GO/GSA results for upregulated pathways are precomputed, comparing conditions within each celltype_minor (uns['GSA_up']) or against the 'Control' reference (uns['GSA_vs_ref_up']).

Inferred Biological Context

The dataset strongly suggests a focus on Alzheimer's Disease research. This inference is based on the presence of AD-specific metadata columns (e.g., NIA, BRAAK, CERAD scores) and conditions like 'E280A' (a known familial AD mutation) and 'Sporadic' AD, within a brain tissue context. The specific diagnosis or stage of AD, however, cannot be definitively confirmed without direct 'Diagnosis' column values.

1. Major Cell Type Score Visualization on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores and the corresponding assigned major cell types on a UMAP (Uniform Manifold Approximation and Projection) dimensionality reduction plot. The major cell type scores (e.g., "HiCAT_major_score: Endothelial cell") represent the transcriptional similarity of each cell to a reference profile for that specific major cell type. The final plot shows the assigned celltype_major for each cell. This visualization is crucial for assessing the quality of cell type annotations and understanding the underlying cellular heterogeneity within the dataset.

Visual Summary

The UMAP plots display the distribution of 43,743 cells in a two-dimensional space. The dataset comprises six major cell types identified in brain tissue: Astrocyte, Endothelial cell, Microglia, Neuron, Oligodendrocyte, and Stromal cell.

• Overall UMAP Structure: The UMAP shows distinct clusters of cells, indicating clear transcriptional separation among different cell populations. There are several large, compact clusters, and some smaller, more diffuse populations.

Cell Type Score Distributions:

• HiCAT_major_score: Endothelial cell: High scores for Endothelial cells are localized to a specific, relatively small cluster on the upper left side of the UMAP, with some dispersion into adjacent areas.
• HiCAT_major_score: Stromal cell: High Stromal cell scores are concentrated in a distinct cluster, predominantly on the upper-left, close to the Endothelial cell cluster, suggesting a close transcriptional relationship or shared developmental origin, or spatial proximity *in vivo*.
• HiCAT_major_score: Microglia: Microglia show a clear, dense cluster with high scores in a region towards the top-middle of the UMAP, distinct from other main clusters.
• HiCAT_major_score: Neuron: Neurons form a large, complex cluster occupying a significant portion of the left and central UMAP space, characterized by high scores for neuronal markers. This cluster appears to be internally heterogeneous.
• HiCAT_major_score: Astrocyte: Astrocytes show a distinct, multi-lobed cluster with high scores in the upper-central and upper-right regions of the UMAP.
• HiCAT_major_score: Oligodendrocyte: Oligodendrocytes form a very large, well-defined cluster dominating the right side of the UMAP, exhibiting uniformly high scores.

• Correspondence with celltype_major: The final celltype_major plot, which assigns each cell to its most likely major type, generally aligns very well with the regions of high scores for each individual HiCAT_major_score plot. Each colored region in the celltype_major plot corresponds to a specific cell type and shows a high concentration of the respective cell type's score. This indicates that the cell type scoring effectively delineates distinct cell populations, confirming the robustness of the major cell type annotations.

Biological Interpretation

The clear segregation of different major cell types on the UMAP, as evidenced by both the HiCAT_major_score plots and the final celltype_major annotation, indicates robust and distinct transcriptional profiles for these cell populations within the human brain tissue.

• Cell Type Identity: The high scores for specific cell types within their corresponding UMAP clusters confirm that the assigned major cell types are well-supported by their transcriptional signatures. For example, the large and distinct cluster of Oligodendrocytes (high HiCAT_major_score: Oligodendrocyte) on the right side of the UMAP reflects their specialized role in myelin formation and distinct gene expression patterns. Similarly, the diverse neuronal populations, while clustered together, show a broad distribution of neuronal scores.
• Brain Cellular Heterogeneity: The UMAP effectively captures the expected cellular heterogeneity of the brain, displaying distinct populations of neurons, glial cells (astrocytes, oligodendrocytes, microglia), and vascular/stromal components (endothelial cells, stromal cells). The spatial separation between these cell types on the UMAP reflects fundamental differences in their biological functions and gene expression programs.
• Annotation Quality: The strong concordance between the continuous cell type scores and the discrete cell type assignments (as seen in celltype_major) suggests a high quality of cell type annotation. Areas with high scores for a particular cell type largely overlap with the assigned cluster for that cell type, minimizing ambiguity in cell identity. The distinct boundaries between the major cell types on the UMAP indicate well-resolved populations, which is crucial for downstream differential expression or pathway analyses.

Annotation Notes

The UMAP visualization of major cell type scores and annotations demonstrates high confidence in the major cell type assignments. The distinct clustering and concentrated high scores for each cell type confirm that the major cell populations are well-separated based on their gene expression profiles. This provides a solid foundation for subsequent analyses that rely on accurate cell type identification, such as condition-specific differential expression or cell-cell interaction studies, especially in the context of brain diseases like Alzheimer's. There are no major anomalies or ambiguities observed in the major cell type annotations that would warrant further investigation at this level.

2. Marker Gene Expression Across Brain Cell Subtypes

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression patterns of identified marker genes across various celltype_subset populations within the human brain single-cell RNA-sequencing dataset. The purpose of this plot is to confirm the identity and distinctness of the annotated cell populations based on the expression of known and newly identified marker genes. Each dot's size represents the fraction of cells within a group expressing a particular gene, while its color intensity indicates the mean expression level of that gene within the group. The analysis was performed with target_cell set to None, indicating a global marker gene discovery across all cell types.

Visual Summary

The dot plot effectively visualizes the specificity and intensity of marker gene expression across 24 distinct brain cell subtypes.

• Highly Specific Expression: The plot exhibits clear diagonal blocks of highly expressed genes, with strong red colors and large dot sizes concentrated within specific celltype_subset populations. This pattern indicates robust and unique marker gene expression for most cell types, reinforcing their assigned identities.
• Astrocyte Markers: Astrocytes are clearly identified by the strong expression of classic markers such as *SLC1A2*, *SLC1A3*, *AQP4*, *GFAP*, and *GLUL*.
• Endothelial and Fibroblast Markers: Endothelial tip cells show distinct expression of *DLL4*, while fibroblasts are characterized by *DCN* and *FBLN1*. Markers like *VIM* and *FN1* show broader expression across endothelial and fibroblast populations, reflecting their mesenchymal origins.
• Microglial Subtypes: The plot provides excellent resolution for different microglial activation states.
  • General microglial markers like *PTPRC*, *ITGAM*, and *MSR1* are observed across microglial groups.
  • Microglia (M1) exhibits prominent expression of pro-inflammatory markers such as *FCGR2A* and *FCGR3A*.
  • Microglia (M2a) is marked by *MRC1* and *CD163*, consistent with an anti-inflammatory or reparative phenotype.
  • Microglia (M2b) displays strong *CD86* and *CD74* expression.
  • Microglia (M2c) is characterized by high *MERTK* and *MSR1* expression.
• Neuronal Subtypes: Diverse neuronal populations are distinguished by neurotransmitter-related genes.
  • GABAergic neurons express *GAD1*, *GAD2*, and *SLC6A1*.
  • Glutamatergic neurons are marked by *SLC17A7*, *GRIN2B*, and *GRIN1*.
  • Dopaminergic neurons show expression of *TH* and *SLC6A3*.
  • Cholinergic neurons express *ACHE*.
  • Adrenergic and Noradrenergic neurons both express *DBH*.
• Oligodendrocyte Lineage: The oligodendrocyte lineage is well-delineated.
  • Oligodendrocyte progenitor cells (OPCs) are identified by *SOX10*, *OLIG2*, *PDGFRA*, and *VCAN*.
  • Mature, myelinating oligodendrocytes show high expression of myelin structural components such as *MBP*, *PLP1*, *MOG*, *MAG*, and *CNTNAP2*.
  • Mature, non-myelinating oligodendrocytes share some markers with myelinating oligodendrocytes but also exhibit distinct expression patterns.
• Smooth Muscle Cells: Smooth muscle cells are clearly identified by markers like *MYL9*, *KCNIP3*, *CALD1*, and *NOTCH3*.

Biological Interpretation

The observed marker gene expression patterns provide strong evidence for the successful identification and robust annotation of distinct cell populations within the brain, consistent with current knowledge of brain cellular diversity.

• Cell Type Validation: The highly specific expression of canonical and novel marker genes for each celltype_subset confirms the biological identity of these populations. For instance, the expression of *GFAP* and *AQP4* in astrocytes is fundamental for their role in brain homeostasis and blood-brain barrier function [GeneCards: GFAP, AQP4]. Similarly, myelin genes (*MBP*, *PLP1*) clearly mark mature oligodendrocytes crucial for neuronal insulation.
• Functional Subtype Resolution: The ability to distinguish between various microglial activation states (M1, M2a, M2b, M2c) is particularly important. These states reflect different functional roles in neuroinflammation, phagocytosis, and tissue repair [PubMed search: microglia activation states brain function]. The precise identification of diverse neuronal subtypes (e.g., glutamatergic, GABAergic, dopaminergic) based on their neurotransmitter machinery is critical for understanding specific neural circuits and their functions [PubMed search: neuronal subtypes neurotransmitter].
• Relevance to Brain Biology and Disease Context (Alzheimer's Disease): Given the inferred biological context of Alzheimer's Disease, the accurate identification and resolution of these cell subtypes are paramount.
  • Microglia: Changes in microglial activation states are central to AD pathology, influencing amyloid-beta clearance, tauopathy, and neuroinflammation. Distinguishing M1 (pro-inflammatory) from M2 (anti-inflammatory/repair) states allows for detailed investigations into their roles in disease progression [PubMed search: microglia Alzheimer's disease pathology].
  • Astrocytes: Reactive astrocytes are a hallmark of AD, and their molecular signature (e.g., *GFAP* upregulation) is crucial for understanding their contribution to neurodegeneration.
  • Neurons and Oligodendrocytes: The precise identification of neuronal subtypes allows for the investigation of selective neuronal vulnerability in AD. Similarly, disruptions in oligodendrocyte function and myelination are increasingly recognized in neurodegenerative diseases.

Annotation Notes

The marker expression dot plot strongly supports the high quality and distinctness of the celltype_subset annotations. The clear segregation of specific markers to individual cell populations, with minimal overlap for the most specific markers, indicates that the clustering and annotation processes have effectively resolved biologically meaningful cell types and their functional states. This robust annotation forms a solid foundation for subsequent differential expression, pathway, and cell-cell interaction analyses aimed at understanding disease mechanisms or therapeutic effects. While some markers show broader expression, this often reflects shared cellular functions or lineage relationships (e.g., mesenchymal markers across fibroblasts and endothelial cells), which is biologically expected. The resolution of microglial activation states and diverse neuronal and oligodendrocyte subtypes is particularly noteworthy and enhances the biological utility of this dataset.

3. Minor Cell Type Population Analysis Across Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the proportional representation of minor cell types within individual samples, categorized by their respective conditions: Control, E280A (familial Alzheimer's Disease), and Sporadic (sporadic Alzheimer's Disease). This allows for a comparative assessment of cell type composition changes associated with different forms of Alzheimer's Disease in the brain tissue.

Visual Summary

The visualization displays the relative proportions of eight minor cell types: Astrocyte, Endothelial cell, Fibroblast, Microglia, Neuron, Oligodendrocyte, Oligodendrocyte progenitor cell, and Smooth muscle cell, across multiple samples for each condition.

• Dominant Cell Types: Neurons (light yellow) and Oligodendrocytes (light green) consistently represent the largest cell populations across all samples and conditions, reflecting the primary cellular composition of brain tissue.
• Control Samples: In control individuals, the cell type proportions are relatively stable. Neurons typically account for approximately 50-70% of cells, and Oligodendrocytes for 20-40%. Other cell types like Astrocytes (dark red) and Microglia (light orange) are present in smaller, consistent proportions.
• E280A Samples (Familial AD): Compared to controls, some E280A samples show a noticeable, albeit modest, decrease in the relative proportion of Neurons, coupled with a slight increase in Astrocytes and Microglia. This shift is apparent in several samples (e.g., E280A 1, 3).
• Sporadic Samples (Sporadic AD): This group exhibits the most prominent alterations in cell type proportions. A more distinct reduction in the relative proportion of Neurons is observed in multiple sporadic samples (e.g., Sporadic 1, 2, 4, 5, 7). Correspondingly, there is a clear and often substantial increase in Astrocytes and Microglia proportions across many sporadic samples, with Astrocytes being particularly elevated in some (e.g., Sporadic 1, 2, 4). Endothelial cell proportions (red-orange) also appear somewhat increased in certain sporadic samples. The variability in cell type composition seems higher within the sporadic group compared to controls.

Biological Interpretation

The observed shifts in cell type populations provide insights into the cellular pathology of Alzheimer's Disease (AD), aligning with known neurodegenerative processes.

• Neuronal Loss in AD: The decreased relative proportion of Neurons in both E280A and Sporadic AD conditions, particularly pronounced in the sporadic form, is a hallmark of AD pathophysiology. Neuronal loss is directly linked to the cognitive decline observed in patients [PubMed search: Alzheimer's neuronal loss].
• Reactive Gliosis and Neuroinflammation: The increased proportions of Astrocytes and Microglia in AD samples, especially in sporadic AD, are indicative of reactive gliosis and neuroinflammation. Astrocytes undergo morphological and functional changes (astrogliosis), while microglia become activated in response to amyloid-beta plaques and neurofibrillary tangles, contributing to the inflammatory cascade and neuronal damage in AD [GeneCards: GFAP (astrocyte marker)], [UniProt: CD68 (microglia marker)].
• Differential Impact on AD Subtypes: The more pronounced cellular changes observed in Sporadic AD compared to E280A could suggest differences in disease severity, progression rates, or specific pathogenic mechanisms between familial and sporadic forms of the disease within this dataset. Familial AD (like E280A) is typically driven by specific genetic mutations leading to altered amyloid processing, while sporadic AD has a more complex etiology.
• Other Cell Types: While less prominent, changes in Oligodendrocyte or Oligodendrocyte progenitor cell populations could suggest involvement of white matter pathology or myelin dysfunction, which are increasingly recognized as contributors to AD pathogenesis. The modest increase in Endothelial cells in some sporadic samples might reflect altered vascular integrity or angiogenic responses in the diseased brain.

Clinical or Translational Implications

The observed cell population shifts have several potential clinical and translational implications:

• Biomarker Discovery: Quantifying cell type proportions could serve as a diagnostic or prognostic biomarker for AD progression. For instance, a higher astrocyte-to-neuron ratio or microglia-to-neuron ratio might correlate with disease severity or stage.
• Therapeutic Targets: The significant involvement of astrocytes and microglia in neuroinflammation highlights these cell types as potential therapeutic targets. Strategies aimed at modulating glial reactivity, reducing neuroinflammation, or promoting neuroprotection could be beneficial.
• Disease Heterogeneity: The variability in cell type composition within the Sporadic AD group underscores the heterogeneity of the disease, suggesting that different patients might exhibit distinct cellular pathologies requiring personalized treatment approaches.

4. Microglial Subpopulation Shifts in Alzheimer's Disease

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different Microglia subsets (M0, M1, M2a, M2b, M2c) within the overall Microglia population for individual samples across three conditions: Control, E280A (familial Alzheimer's Disease), and Sporadic (sporadic Alzheimer's Disease). This visualization helps to understand the impact of Alzheimer's Disease pathology on the cellular states of microglia, crucial immune cells of the brain.

Visual Summary

The stacked bar plots display the proportional distribution of five distinct microglial subsets across individual samples for each condition:

• Control Group: Samples from the control group consistently show a predominant population of Microglia (M0), represented by the deep maroon color, typically accounting for 85-95% of the total microglia. Minor contributions from Microglia (M2c) are observed, with negligible presence of M1, M2a, and M2b subsets.
• E280A Group: In samples from individuals with the E280A mutation (familial AD), there is a noticeable reduction in the relative proportion of Microglia (M0) compared to controls. The M0 population appears to range from approximately 65-90%. Concurrently, there is an increase in the proportions of Microglia (M2a) (light yellow) and Microglia (M2c) (teal/mint green) across most E280A samples. Microglia (M1) and (M2b) remain in very low proportions.
• Sporadic Group: Samples from individuals with sporadic Alzheimer's Disease exhibit a pattern similar to the E280A group. The proportion of Microglia (M0) is generally decreased compared to controls, often appearing lower than in some E280A samples, ranging from 60-90%. Correspondingly, there is an increased presence of Microglia (M2a) and Microglia (M2c). Some sporadic samples also show a slight increase in Microglia (M2b) compared to the other two groups, although M1 remains minimal across all conditions.

Biological Interpretation

Microglia are the primary immune cells of the brain and play a pivotal role in the pathogenesis of Alzheimer's Disease (AD). They can adopt various activation states, broadly categorized into pro-inflammatory (M1-like) and anti-inflammatory/reparative (M2-like) phenotypes, although this spectrum is increasingly recognized as more complex and continuous.

The observed shifts in microglial populations suggest a dynamic response to AD pathology:

• Decrease in M0 Microglia: The consistent reduction in the 'resting' or 'homeostatic' Microglia (M0) population in both E280A and Sporadic AD samples indicates that a significant proportion of microglia are activated and polarized into different states in the diseased brain.
• Increase in M2-like Microglia (M2a, M2c): The most prominent change is the increase in Microglia (M2a) and (M2c) subsets in AD conditions. M2a microglia are typically associated with alternative activation, tissue repair, and immunosuppression, while M2c microglia are involved in phagocytosis of apoptotic cells, tissue remodeling, and deactivation. This shift towards M2-like phenotypes could represent a compensatory mechanism attempting to clear amyloid-beta plaques, mitigate neuroinflammation, and promote tissue repair in response to AD-related damage [1]. However, in chronic neurodegenerative diseases like AD, this M2 activation might be dysfunctional or insufficient to overcome the ongoing pathology, potentially even contributing to disease progression under certain contexts [2].
• Minimal M1 Microglia: The consistently low proportions of M1 microglia, generally associated with pro-inflammatory responses and neurotoxicity, suggest that a widespread, acute pro-inflammatory M1-driven response might not be the dominant microglial phenotype across these samples, or that such a state is transient or spatially restricted. This observation might point towards a chronic, potentially smoldering or dysregulated M2-mediated inflammatory environment in the studied AD brain tissue.
• Similarities between Familial (E280A) and Sporadic AD: The largely similar patterns of microglial subset shifts in both E280A and Sporadic AD suggest common pathways of microglial response to neurodegeneration, despite the distinct genetic and idiopathic origins of these AD forms.

Clinical or Translational Implications

The observed shifts in microglial populations hold significant implications for understanding AD pathogenesis and developing therapeutic strategies:

• Biomarker Potential: The relative proportions of microglial subsets, particularly the M0 to M2 shift, could serve as potential biomarkers for AD progression or response to treatment, measurable through advanced imaging or cerebrospinal fluid analysis if cellular markers are validated.
• Therapeutic Targeting: Modulating microglial activation states represents a promising therapeutic avenue for AD. Strategies aimed at enhancing beneficial M2 functions (e.g., amyloid clearance, neuroprotection) or re-balancing microglial activation away from detrimental states could be explored. The data suggest that interventions aiming to restore homeostatic M0 states or enhance specific M2 functions (M2a, M2c) might be more relevant than solely focusing on suppressing M1 in this context [3].
• Disease Understanding: The observed microglial polarization patterns contribute to the growing understanding that microglia in AD undergo complex and potentially maladaptive changes. Further research into the specific molecular mechanisms driving these M2a/M2c shifts and their functional consequences in both familial and sporadic AD could reveal critical insights into disease mechanisms.

---

References

1. Microglial M2 activation in Alzheimer's Disease: PubMed Search: microglia M2 Alzheimer's disease
2. Dysfunctional Microglia in Alzheimer's Disease: PubMed Search: dysfunctional microglia Alzheimer's disease
3. Therapeutic modulation of microglia in AD: PubMed Search: Alzheimer's disease microglia therapeutic modulation

5. Microglial Subset Population Shifts in Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportions of specific microglial subsets, namely Microglia (M2b) and Microglia (M0), across different conditions related to Alzheimer's Disease: Sporadic AD, E280A (a familial form of AD), and Control subjects. Box plots visualize the distribution of celltype proportions for each subset, with statistical significance determined by pairwise comparisons between conditions using a p-value cutoff of 0.1.

Visual Summary

The box plots illustrate the distribution of celltype proportions for two microglial subsets across the three conditions:

Microglia (M2b) Proportions:

• The proportion of Microglia (M2b) cells is notably higher in the Sporadic AD condition compared to both E280A and Control groups.
• A statistically significant difference (p=0.0202) is observed, indicating a higher proportion of Microglia (M2b) in Sporadic AD subjects compared to Control subjects.
• The E280A condition shows an intermediate proportion of Microglia (M2b) cells, appearing lower than Sporadic AD but higher than Control, though these differences did not meet the statistical significance threshold (Sporadic vs E280A: p=0.435; E280A vs Control: p=0.103, which is slightly above the 0.1 cutoff).

Microglia (M0) Proportions:

• The proportion of Microglia (M0) cells demonstrates an inverse trend compared to M2b, with the Control group exhibiting the highest proportions.
• A statistically significant decrease (p=0.0463) in Microglia (M0) proportion is observed in Sporadic AD subjects compared to Control subjects.
• Similar to M2b, the E280A condition shows intermediate proportions of Microglia (M0) cells, falling between Sporadic AD and Control, but without statistically significant differences from either group (Sporadic vs E280A: p=0.503; E280A vs Control: p=0.127).

Biological Interpretation

The observed shifts in microglial subset proportions highlight distinct immune responses in Alzheimer's Disease, particularly in the Sporadic form:

• Increased Microglia (M2b) in Sporadic AD: The significant increase in M2b microglial proportion in Sporadic AD suggests a specific activation or polarization state of microglia in this disease context. M2b microglia are a distinct M2-like phenotype often associated with antigen presentation, immune regulation, and sometimes with the release of both pro- and anti-inflammatory cytokines. Their elevated presence could indicate a chronic, dysregulated immune response in Sporadic AD, potentially involved in attempting to clear amyloid-beta plaques or manage neuroinflammation, but possibly failing to resolve the pathology effectively.
• Decreased Microglia (M0) in Sporadic AD: The significant reduction in M0 (unpolarized or 'resting') microglia proportion in Sporadic AD implies a widespread activation or polarization of microglia away from a quiescent state. This supports the notion that the microglial population undergoes substantial changes in AD, becoming more "activated" (though not necessarily in a uniformly beneficial or detrimental way, given the complexity of microglial phenotypes). The shift from M0 to other polarized states, including M2b, could be a hallmark of disease progression or an altered microenvironment.
• E280A as an Intermediate State: For both subsets, the E280A familial AD condition tends to show proportions intermediate between Sporadic AD and Control. While these differences did not reach statistical significance in these specific pairwise comparisons, this pattern might suggest different kinetics or magnitudes of microglial activation compared to sporadic AD, potentially due to the earlier onset or distinct genetic drivers of the E280A mutation. Further investigation with a larger sample size or more refined subtyping could clarify these trends.

Clinical or Translational Implications

These findings suggest that distinct microglial activation states, specifically the balance between M0 and M2b-like phenotypes, are altered in Sporadic Alzheimer's Disease.

• Biomarker Potential: Changes in the proportions of M2b and M0 microglia could serve as potential biomarkers for the neuroinflammatory status in different forms of AD.
• Therapeutic Targeting: Understanding the functional implications of increased M2b and decreased M0 microglia in Sporadic AD could open avenues for targeted therapeutic interventions. Modulating specific microglial states to promote beneficial functions (e.g., efficient amyloid clearance, neuroprotection) while suppressing detrimental ones (e.g., chronic pro-inflammatory responses) represents a promising strategy for AD treatment.
• Disease Heterogeneity: The differences observed, and the intermediate nature of E280A, underscore the potential heterogeneity in immune responses between familial and sporadic forms of AD, which may require tailored therapeutic approaches.

6. Cell-Cell Interaction Patterns in Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates significant cell-cell interaction (CCI) patterns across different conditions (Control, E280A familial Alzheimer's Disease (AD), and Sporadic AD) within human brain tissue. Using CellPhoneDB, ligand-receptor interactions with a p-value cutoff of 0.05 and a mean expression cutoff of 0.01 were identified for various cell-cell pairs. The visualization presents the top 80 most significant interactions per condition, where the size of each dot represents the -log10(p-value) (larger dot = more significant) and the color intensity reflects the log2(mean) expression of the interacting ligand-receptor pair (brighter color = higher expression). This provides insights into altered intercellular communication in AD pathogenesis.

Visual Summary

The dot plots reveal distinct and common cell-cell interaction signatures across the three conditions:

• Control Condition: A baseline of diverse cell-cell interactions is observed, with prominent signals for glutamatergic signaling (Glutamate_byGLS_and_SLC gene pairs), synaptic adhesion (NRXN-NLGN pairs), cholesterol transport (Cholesterol_byLRP_and_APOE), and some neuroinflammatory (SPP1-integrin) and vascular (VEGFA) interactions. Neuron-Neuron, Neuron-Oligodendrocyte, and Astrocyte-Neuron interactions show considerable activity.
• E280A Condition (Familial Alzheimer's Disease): Compared to Control, the E280A condition exhibits a marked increase in the prevalence and signal strength (indicated by larger, brighter dots) of several key interaction pathways:
  • Glutamatergic Signaling: A striking expansion and intensification of Glutamate_byGLS_and_SLC interactions are observed across numerous cell-cell pairs, particularly Neuron-Neuron, Neuron-Oligodendrocyte, Oligodendrocyte-Neuron, and Astrocyte-Neuron.
  • Synaptic Adhesion: NRXN-NLGN interactions also show increased activity and mean expression, primarily within Neuron-Neuron and Neuron-Oligodendrocyte pairs, suggesting altered synaptic integrity.
  • Cholesterol Transport: Cholesterol_byLRP_and_APOE interactions become more prominent, especially involving Oligodendrocyte-Neuron and Astrocyte-Neuron, indicating dysregulated lipid metabolism.
  • Neuroinflammation: SPP1-integrin interactions involving Microglia (Microglia-Neuron, Microglia-Astrocyte) remain robust and potentially intensified, suggesting ongoing inflammatory processes.
  • PTPRD and ADGRL interactions: Interactions involving PTPRD and TENM3_FLRT3_cotrans_ADGRL also appear more prevalent and stronger across neuronal and glial interactions.
  • VEGFA interactions are less represented among the top 80 interactions compared to Control.
• Sporadic Condition (Sporadic Alzheimer's Disease): The interaction landscape in Sporadic AD largely mirrors that of the E280A familial AD condition.
  • The widespread and strong activity of Glutamate_byGLS_and_SLC and NRXN-NLGN interactions is consistently observed across various neuronal and glial cell-cell pairs, similar to E280A.
  • Cholesterol_byLRP_and_APOE interactions are also notably prominent, especially between Oligodendrocyte-Neuron and Astrocyte-Neuron, reinforcing the observation of altered lipid handling.
  • SPP1-integrin interactions persist in microglia-related pairs, indicative of sustained neuroinflammation.
  • Similar to E280A, VEGFA interactions are less prominent in the top 80 interactions compared to Control.

In summary, both familial (E280A) and sporadic AD conditions exhibit a convergent pattern of intensified cell-cell communication related to synaptic function, lipid metabolism, and neuroinflammation, reflecting profound alterations in the brain's intercellular network.

Biological Interpretation

The observed changes in cell-cell interaction patterns provide significant biological insights into Alzheimer's Disease pathology:

• Dysregulation of Synaptic Function and Excitotoxicity: The striking increase in glutamatergic signaling (Glutamate_byGLS_and_SLC pairs) across neuronal and glial cell types in both AD conditions is highly indicative of synaptic dysfunction and potential excitotoxicity. Aberrant glutamatergic transmission is a known contributor to neuronal damage and cognitive decline in AD. Concurrently, the elevated NRXN-NLGN interactions, critical for synapse formation and stability, suggest widespread alterations in synaptic organization, potentially reflecting dysfunctional compensatory mechanisms or disrupted synaptic plasticity in the disease state PubMed: Glutamatergic signaling Alzheimer's Disease GeneCards: GRM1 GeneCards: NRXN1.
• Altered Lipid Homeostasis and APOE Pathway Perturbation: The enhanced prominence of Cholesterol_byLRP_and_APOE interactions, particularly involving oligodendrocytes, neurons, and astrocytes, underscores the critical role of lipid metabolism in AD. APOE is a major genetic risk factor for AD, involved in cholesterol transport, lipid homeostasis, and amyloid-beta clearance. Dysregulation of these pathways can compromise neuronal membrane integrity, synaptic function, and contribute to amyloid plaque formation PubMed: APOE cholesterol Alzheimer's Disease GeneCards: APOE.
• Persistent Neuroinflammation and Microglial Activation: The robust presence and potential increase in SPP1-integrin interactions involving microglia in AD conditions are consistent with an ongoing state of neuroinflammation. SPP1 (Osteopontin) is a cytokine often upregulated in AD brains, contributing to microglial activation, immune cell recruitment, and modulation of plaque pathology and neuronal damage. These interactions highlight the detrimental role of chronically activated microglia in AD progression PubMed: SPP1 integrin Alzheimer's Disease microglia GeneCards: SPP1.
• Dysregulated Neuro-Glial Communication: The widespread changes in interactions between neurons and supporting glial cells (oligodendrocytes and astrocytes) suggest a profound disruption in neuro-glial cross-talk. This communication is essential for neuronal health, myelination, metabolic support, and clearance of cellular debris. Alterations in these interactions likely contribute to the broader cellular dysfunction observed in AD.
• Convergent Pathology in Familial and Sporadic AD: The remarkable similarities in altered CCI patterns between E280A (familial AD) and Sporadic AD indicate that despite different initiating factors, these two forms of the disease converge on common downstream pathogenic mechanisms involving dysregulated synaptic function, lipid metabolism, and neuroinflammation.

Clinical or Translational Implications

The identified alterations in cell-cell interaction patterns have significant clinical and translational implications for Alzheimer's Disease:

• Therapeutic Target Prioritization: The specific ligand-receptor pairs showing significant dysregulation in AD conditions, such as those involved in Glutamate_byGLS_and_SLC (glutamatergic signaling), NRXN-NLGN (synaptic adhesion), Cholesterol_byLRP_and_APOE (lipid transport), and SPP1-integrin (neuroinflammation), represent high-priority therapeutic targets. Modulating these interactions could potentially restore synaptic function, mitigate excitotoxicity, reduce neuroinflammation, and improve lipid homeostasis, thereby slowing or halting disease progression.
• Biomarker Development: Changes in the expression levels or interaction patterns of these specific ligand-receptor pairs could serve as valuable biomarkers for AD diagnosis, staging, or monitoring treatment efficacy. For example, specific serum or CSF levels of interacting proteins or their components could reflect the underlying cellular communication dysregulation.
• Experimental Validation and Drug Discovery: These findings provide a strong foundation for further experimental validation using advanced *in vitro* (e.g., neuron-glial co-cultures) and *in vivo* (e.g., AD animal models) studies. Interventions specifically designed to block or enhance these identified interactions (e.g., small molecule inhibitors, antibodies, gene therapies) can be tested for their therapeutic potential. For instance, exploring compounds that fine-tune glutamatergic signaling or block specific inflammatory pathways involving SPP1 could be promising.
• Understanding Disease Heterogeneity: While significant commonalities exist between familial and sporadic AD at the CCI level, subtle differences may also be present. Further detailed analysis could reveal unique interaction signatures that contribute to the observed heterogeneity in disease presentation and progression, potentially leading to personalized therapeutic strategies.

7. Condition-Specific Cell-Cell Interaction Patterns in Alzheimer's Disease

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interactions (CCIs) among major brain cell types (Neuron, Oligodendrocyte, Astrocyte, Microglia) across different conditions: Control, E280A (a familial Alzheimer's Disease mutation), and Sporadic Alzheimer's Disease. The aim is to identify CCIs that exhibit significant differences in strength and significance between these conditions, providing insights into altered intercellular communication in Alzheimer's pathology. The CellPhoneDB tool was used to infer these interactions, and the results are presented as a dot plot, where dot size reflects the -log10(p-value) of the interaction and color intensity represents the scaled log strength of the interaction.

Visual Summary

The dot plot displays a complex landscape of cell-cell interactions, with clear condition-specific patterns. Each row represents a distinct sample, grouped by condition (Control, E280A, Sporadic), and each column represents a unique cell-cell interaction (CCI Index).

• Control samples generally show a high density of strong interactions (large, dark red dots) across a wide range of CCI pairs, particularly in the left portion of the plot. This suggests robust and diverse intercellular communication in the healthy brain.
• E280A samples exhibit a distinct pattern, with some interactions showing reduced strength compared to controls, while others are maintained or appear uniquely upregulated. A noticeable cluster of interactions, particularly those involving GABAergic signaling, appear prominent in E280A.
• Sporadic samples present another unique signature, characterized by a shift in prominent interactions. Many interactions toward the right side of the plot, frequently involving glutamatergic signaling pathways, display consistently high strength and significance (large, dark red dots) in sporadic AD samples, often surpassing their levels in control and E280A groups.

Overall, the visualization effectively highlights distinct "signatures" of altered cell-cell communication associated with familial (E280A) and sporadic forms of Alzheimer's Disease, contrasting them with the control state.

Biological Interpretation

The observed condition-specific CCI patterns reveal significant alterations in key signaling pathways related to neuronal function, glial support, and neuroinflammation in Alzheimer's Disease.

Interactions Prominent in Control, Diminished in Alzheimer's Conditions

Several interactions, strong and consistent in control samples, appear reduced or disrupted in both E280A and Sporadic conditions. These often involve cell adhesion and neurotrophic support.

THY1_integrin_aMb2_complex -- Neuron | Oligodendrocyte

• Signaling/Mechanism: THY1 (CD90) is a GPI-anchored glycoprotein involved in cell adhesion, T-cell activation, and neuron regeneration. Integrins (like αMβ2, also known as Mac-1 or CD11b/CD18) are critical for cell adhesion and migration. This interaction likely facilitates neuron-oligodendrocyte adhesion and communication, important for myelination and neuronal support.
• Biological Role: In the healthy brain, these interactions might be crucial for maintaining the structural integrity of neuronal circuits and proper oligodendrocyte function, including myelination and metabolic support to neurons.
• AD Context: Their reduction in AD conditions suggests a potential breakdown in essential neuron-oligodendrocyte interactions, contributing to demyelination, synaptic dysfunction, and neuronal vulnerability. GeneCards: THY1

NCAM1_FGFR1 -- Neuron | Oligodendrocyte

• Signaling/Mechanism: NCAM1 (Neural Cell Adhesion Molecule 1) plays a vital role in cell adhesion, neuronal plasticity, and synapse formation. FGFR1 (Fibroblast Growth Factor Receptor 1) is a tyrosine kinase receptor involved in neurodevelopment, neuronal survival, and glial cell proliferation.
• Biological Role: This interaction is critical for mediating neuron-glia communication, promoting neuronal survival, and supporting oligodendrocyte differentiation and myelination in the healthy brain.
• AD Context: The diminished strength in AD conditions could indicate impaired neurotrophic support and reduced plasticity, contributing to neuronal loss and white matter pathology characteristic of AD. PubMed: NCAM1 FGFR1 neuron oligodendrocyte

Interactions Prominent in E280A (Familial AD)

The E280A condition shows a distinct set of prominent interactions, often related to specific neurotransmitter systems and APP processing.

GABA_byGAD2_and_SLC6A1_GABBR1 -- Neuron | Oligodendrocyte

• Signaling/Mechanism: This interaction involves GABA, the primary inhibitory neurotransmitter. GAD2 (Glutamate Decarboxylase 2) synthesizes GABA. SLC6A1 (GABA transporter 1, GAT1) reuptakes GABA. GABBR1 (GABA-B Receptor type 1) is a G-protein coupled receptor for GABA, mediating slow, prolonged inhibitory responses.
• Biological Role: Dysregulation of GABAergic signaling is a prominent feature in AD, contributing to neuronal hyperexcitability and cognitive decline. This specific interaction suggests significant GABAergic signaling between neurons and oligodendrocytes, possibly reflecting compensatory or pathological changes in inhibitory tone in familial AD.
• AD Context: Altered GABAergic signaling can impact neuronal network activity, synaptic plasticity, and contribute to cognitive deficits. Targeting GABA-B receptors has been explored for neuroprotection. GeneCards: GABBR1

APP_SORL1 -- Neuron | Oligodendrocyte

• Signaling/Mechanism: APP (Amyloid Beta Precursor Protein) is central to AD pathology, as its proteolytic cleavage products include amyloid-beta (Aβ). SORL1 (Sortilin Related Receptor L(DLR Class) A Repeat Containing 1) is a receptor involved in APP trafficking and processing, influencing Aβ generation and clearance.
• Biological Role: This direct interaction between APP and SORL1 on neurons and oligodendrocytes highlights a crucial pathway influencing Aβ metabolism in the E280A context. SORL1 is a known genetic risk factor for sporadic AD, but its role here in familial AD interactions suggests broad relevance.
• AD Context: Enhanced interaction could reflect disrupted APP trafficking or impaired Aβ clearance, directly contributing to amyloid pathology in familial AD. PubMed: APP SORL1 Alzheimer

Interactions Prominent in Sporadic AD

Sporadic AD samples exhibit strong interactions primarily involving glutamatergic signaling and inflammatory processes, suggesting distinct pathological drivers.

Glutamate_byGLS2_and_SLC1A3_GRM1 -- Neuron | Astrocyte

• Signaling/Mechanism: Glutamate is the major excitatory neurotransmitter. GLS2 (Glutaminase 2) converts glutamine to glutamate. SLC1A3 (excitatory amino acid transporter 1, EAAT1) is an astrocytic transporter responsible for glutamate reuptake from the synaptic cleft, preventing excitotoxicity. GRM1 (Metabotropic Glutamate Receptor 1) on neurons modulates synaptic transmission and neuronal excitability.
• Biological Role: Sustained high levels of these interactions suggest dysregulated glutamatergic signaling. Given that SLC1A3 is an astrocyte-specific transporter, this highlights a critical role for astrocytes in maintaining glutamate homeostasis, which is severely compromised in AD.
• AD Context: Upregulated glutamatergic signaling and impaired astrocytic glutamate clearance are hallmarks of excitotoxicity in AD, leading to neuronal damage and death. This is a prominent feature differentiating sporadic AD from controls and even E280A in this dataset. GeneCards: GRM1, GeneCards: SLC1A3

APP_CD74 -- Oligodendrocyte | Microglia

• Signaling/Mechanism: APP, as discussed, is central to AD. CD74 (Invariant Chain) is a transmembrane protein primarily associated with MHC class II molecules, involved in antigen presentation and immune responses. It is expressed by microglia and other immune cells.
• Biological Role: This interaction suggests a role for microglia in processing or responding to APP products, potentially linking oligodendrocytes to microglial inflammatory responses or antigen presentation in sporadic AD.
• AD Context: Microglial activation and neuroinflammation are key features of AD. This interaction points to a specific inflammatory pathway involving APP that is prominent in sporadic AD, potentially driving disease progression. PubMed: APP CD74 microglia Alzheimer

NRXN3_LRRTM4 -- Neuron | Neuron

• Signaling/Mechanism: Neurexins (NRXN) are presynaptic adhesion molecules that interact with postsynaptic partners to mediate synapse formation and function. LRRTM4 (Leucine Rich Repeat Transmembrane Neuronal 4) is a postsynaptic protein important for excitatory synapse organization.
• Biological Role: This interaction is critical for maintaining proper synaptic structure and function between neurons.
• AD Context: The strong presence of this interaction in sporadic AD might indicate an attempt at compensatory synaptic remodeling, or a specific type of synaptic dysfunction or reorganization that contributes to the cognitive decline seen in sporadic AD. PubMed: Neurexin LRRTM synapse Alzheimer

Clinical or Translational Implications

The identification of condition-specific cell-cell interactions provides a powerful framework for understanding AD pathogenesis and identifying novel therapeutic targets.

Restoring Neuro-Glial Support and Connectivity

• The diminished THY1-integrin and NCAM1-FGFR1 interactions in AD conditions highlight a loss of crucial neuron-oligodendrocyte communication. Therapeutic strategies could focus on enhancing these interactions, potentially through small molecules or biologics designed to promote cell adhesion and neurotrophic signaling, which may protect against demyelination and neuronal degeneration.

Modulating Neurotransmitter Dysregulation

• GABAergic System (E280A): The prominence of GABA-GABBR1 signaling in E280A suggests specific GABAergic alterations in familial AD. Modulators of GABA-B receptors could be investigated to rebalance inhibitory neurotransmission, aiming to reduce hyperexcitability and improve cognitive function. Clinical trials for GABAergic modulators have shown promise in other neurological disorders.
• Glutamatergic Excitotoxicity (Sporadic AD): The highly active Glutamate-GRM1 and related interactions in sporadic AD point to significant excitotoxicity. Therapeutic interventions could involve targeting astrocytic glutamate transporters (e.g., enhancing SLC1A3 function) or modulating metabotropic glutamate receptors (GRM1 antagonists) to reduce excessive excitatory signaling and prevent neuronal damage. Memantine, an NMDA receptor antagonist, is an existing AD drug that mitigates glutamatergic excitotoxicity.

Targeting APP Processing and Clearance Pathways

• The APP-SORL1 interaction in E280A is a direct link to amyloid pathology. Therapies aimed at enhancing SORL1 function or modulating its interaction with APP could improve APP trafficking and Aβ clearance, offering a strategy to reduce amyloid burden.
• The APP-CD74 interaction in sporadic AD suggests an inflammatory component related to APP. Targeting CD74 or downstream inflammatory pathways in microglia could dampen neuroinflammation, which is a significant contributor to AD progression.

Addressing Synaptic Dysfunction

• The altered Neurexin-LRRTM interactions in sporadic AD indicate specific changes in synaptic organization. Therapeutic approaches might focus on agents that stabilize or restore synaptic integrity, potentially by modulating the expression or function of these synaptic adhesion molecules.

In summary, these findings underscore the heterogeneous nature of AD across its familial and sporadic forms at the cellular communication level. Future therapeutic strategies may need to consider these distinct pathological signatures for more personalized and effective interventions.

8. Neuron Surfaceome Marker Expression Across Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot visualization of surfaceome marker expression in neuronal cells, comparing different conditions: Control, E280A (a familial Alzheimer's Disease mutation), and Sporadic Alzheimer's Disease. The markers were identified as differentially expressed when comparing each condition against the Control group using specific filtering criteria (nz_pct_score and nz_pct_FC). The aim is to highlight surface-accessible proteins that show condition-specific expression patterns in neurons, offering insights into disease mechanisms and potential therapeutic targets.

Visual Summary

The dot plot displays the expression of selected surfaceome markers across individual patient samples within each of the three conditions: Control, E280A, and Sporadic.

• Expression Intensity and Prevalence: The color intensity of each dot indicates the mean expression level of a gene within the group (darker red signifies higher mean expression), while the size of the dot represents the fraction of cells in that group expressing the gene (larger dots indicate expression in a higher percentage of cells).

Condition-Specific Patterns:

• Control-Enriched Markers: The leftmost cluster of genes, including *SLC26A3*, *EPHA6*, *GRM1*, *PTPRB*, and *CSMD2*, generally shows higher expression (darker red, larger dots) in Control samples compared to E280A and Sporadic samples. This suggests these genes might be important for healthy neuronal function. However, there is some variability within the control group, with some samples showing lower expression for certain markers.
• E280A-Enriched Markers: A distinct set of genes, such as *ADAM10*, *HTR1E*, *EPHA7*, *LRRK2*, *IGSF11*, and *RNF13*, exhibits elevated expression in E280A samples. This pattern points to molecular alterations specific to familial Alzheimer's Disease neurons.
• Sporadic-Enriched Markers: Genes like *LRFN2*, *CNTN3*, *PLXDC2*, *ADCY9*, *ANO5*, and *SORCS1* demonstrate increased expression in Sporadic Alzheimer's Disease samples. This cluster highlights markers potentially associated with the more common, non-familial form of AD.

• Shared and Distinct Markers: While distinct clusters of markers are evident for each condition, some genes, such as *GRM1*, appear in more than one condition's associated marker list, potentially indicating different roles or expression patterns depending on the specific disease context or isoforms. Some markers at the far right (e.g., *ADGRV1*, *IGF2R*, *PTPRB*, *ANTXR1*) show relatively high expression across all conditions, suggesting broad neuronal expression, though they might still be differentially regulated when compared to controls.

Biological Interpretation

The identified surfaceome markers provide insights into neuronal functions perturbed in Alzheimer's Disease, encompassing synaptic integrity, neurotransmission, and protein processing.

Markers Enriched in Control Neurons (Potentially Indicative of Healthy Neuronal Function)

• GRM1 (Glutamate Receptor Metabotropic 1): This G-protein coupled receptor plays a critical role in excitatory neurotransmission, synaptic plasticity, and neuronal excitability through its involvement in the metabotropic glutamate receptor signaling pathway. Its robust expression in control neurons suggests its importance for maintaining normal cognitive function. Downregulation or dysfunction of GRM1 in AD could contribute to synaptic impairment and cognitive decline GeneCards: GRM1.
• EPHA6 (Ephrin Receptor A6): A receptor tyrosine kinase involved in cell-cell recognition and signaling, crucial for axon guidance, dendritic spine morphogenesis, and synaptic plasticity. EPHA6 signaling helps establish and maintain neural circuits. Its reduced presence in AD neurons could point to deficits in neuronal structural integrity and connectivity PubMed: EPHA6 and neuronal plasticity.
• PTPRB (Protein Tyrosine Phosphatase Receptor Type B): Also known as VE-PTP, this receptor-type protein tyrosine phosphatase is involved in endothelial cell junctions, but also expressed in neurons where it can influence cell adhesion and signaling pathways relevant to neuronal development and function. Its specific role in healthy neuronal populations warrants further investigation, but its reduction in disease states could indicate compromised cellular adhesion or signaling regulation.

Markers Enriched in E280A Neurons (Specific to Familial Alzheimer's Disease)

• ADAM10 (ADAM Metallopeptidase Domain 10): A crucial "alpha-secretase" responsible for cleaving Amyloid Precursor Protein (APP) within the Aβ sequence, thereby preventing the formation of amyloid-beta (Aβ) peptides and promoting the non-amyloidogenic pathway. Decreased ADAM10 activity is a hallmark of AD pathology, leading to increased Aβ production. Its *increased* expression in E280A neurons might represent a compensatory mechanism against increased APP processing towards the amyloidogenic pathway due to the E280A mutation in presenilin-1 (PSEN1), or it could reflect altered proteolytic landscapes GeneCards: ADAM10.
• HTR1E (5-Hydroxytryptamine Receptor 1E): A serotonin receptor belonging to the G-protein coupled receptor family. The serotonergic system plays a vital role in regulating mood, sleep, appetite, and cognition. Dysfunction of this system and altered serotonin receptor expression are observed in AD, potentially contributing to neuropsychiatric symptoms and cognitive deficits PubMed: HTR1E Alzheimer's Disease.
• EPHA7 (Ephrin Receptor A7): Similar to EPHA6, EPHA7 is a receptor tyrosine kinase involved in synaptic organization, dendritic spine maturation, and neuronal migration. Its altered expression in E280A neurons could indicate specific disruptions in synaptic architecture and function characteristic of familial AD pathogenesis UniProt: EPHA7.

Markers Enriched in Sporadic Neurons (Associated with General Alzheimer's Disease Pathology)

• LRFN2 (Leucine Rich Repeat And Fibronectin Type III Domain Containing 2): A synaptic cell adhesion molecule that promotes excitatory synapse formation and maturation. Its dysregulation in sporadic AD neurons could directly contribute to synaptic loss and dysfunction, a key pathological feature of AD and a major correlate of cognitive decline GeneCards: LRFN2.
• ADCY9 (Adenylate Cyclase 9): An enzyme that catalyzes the synthesis of cyclic AMP (cAMP), a crucial second messenger in numerous intracellular signaling pathways vital for neuronal plasticity, long-term potentiation, and memory formation. Altered cAMP signaling has been implicated in AD, affecting processes like neuronal survival and amyloid-beta clearance. Increased ADCY9 might represent an attempt to compensate for reduced cAMP signaling or contribute to dysregulated signaling PubMed: ADCY9 Alzheimer's.
• SORCS1 (Sortilin Related VPS10P Domain Containing Receptor 1): This receptor is involved in protein sorting and trafficking, particularly for APP and BACE1, thereby influencing Aβ generation and clearance. Polymorphisms in *SORCS1* are associated with an increased risk of late-onset AD. Its enrichment in sporadic AD neurons suggests a role in altered protein trafficking and amyloidogenic processing in the absence of specific genetic mutations GeneCards: SORCS1.

Clinical or Translational Implications

The identification of these neuron-specific surfaceome markers provides valuable candidates for therapeutic development and diagnostic applications in Alzheimer's Disease.

Therapeutic Targets:

• ADAM10: The observation of increased ADAM10 in E280A neurons, if confirmed as a compensatory response, suggests that strategies to enhance its activity or stability could be beneficial in inhibiting Aβ production. Therapeutic approaches focused on upregulating alpha-secretase activity are a long-standing interest in AD drug development.
• HTR1E: Given the involvement of serotonin receptors in mood, cognition, and sleep disturbances in AD, targeting HTR1E or other serotonin receptors could offer symptomatic relief for neuropsychiatric symptoms often associated with the disease. Serotonergic modulators are already used in psychiatry, providing a precedent for drug development.
• Synaptic Adhesion Molecules (e.g., EPHA6, EPHA7, LRFN2): Molecules critical for synaptic integrity and plasticity (Ephrin receptors, LRFN2) represent potential targets to counter synaptic loss in AD. Modulating their function could help restore synaptic connections and improve cognitive function. This might involve small molecules or biologics designed to stabilize or enhance their signaling.
• SORCS1: As a regulator of APP processing and trafficking, SORCS1 presents an interesting target. Strategies to modulate SORCS1 activity or expression could influence the balance between amyloidogenic and non-amyloidogenic pathways, potentially reducing Aβ burden.

• Biomarker Potential: Genes showing significant and consistent differential expression, particularly those on the cell surface, could serve as novel biomarkers for diagnosing AD, stratifying patients (e.g., familial vs. sporadic), or monitoring disease progression and treatment response. Further validation using clinical samples and imaging techniques would be necessary.
• Experimental Validation: The identified markers warrant further experimental validation using in vitro models (e.g., patient-derived iPSC neurons) and in vivo models (e.g., AD mouse models) to confirm their functional roles in AD pathogenesis and to test the efficacy of targeting them with therapeutic agents. Given these are surfaceome markers, they are inherently more accessible for antibody-based therapies or cell-based diagnostics.

9. Microglial Condition-Specific Surfaceome Markers in Alzheimer's Disease

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Microglia across Control, E280A (familial AD), and Sporadic (non-familial AD) conditions. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing a gene (dot size) for selected markers in individual samples. The analysis utilized differentially expressed genes (DEG) comparing each condition against the reference condition (Control), focusing on surfaceome markers to identify potential therapeutic targets or biomarkers for Alzheimer's Disease.

Visual Summary

The dot plot displays the expression patterns of 40 Microglia surfaceome markers across 18 individual samples, grouped by condition (Control, E280A, Sporadic). Each row represents a sample, and each column represents a marker gene.

• Control-Specific Markers (Leftmost Red Box): A distinct cluster of markers, including CX3CR1, ITGAM, SEMA4D, DAGLB, SPNS2, SLC7A6, MRC1, LILRB1, CLSTN1, LINGO1, SLC43A2, MRC2, GLDN, RNF149, DSCAM, SLC11A1, and RNF13, shows high expression levels (dark red dots) and a high fraction of expressing cells (large dot size) predominantly within the Control samples. These markers appear to be downregulated or expressed at lower levels in E280A and Sporadic samples. This pattern suggests a shift in microglial phenotype from a 'surveillance' or homeostatic state in Control to an altered state in AD conditions.
• E280A/Sporadic-Enriched Markers (Middle and Right Red Boxes): Another set of markers, including MSR1, OLR1, IFNGR2, MS4A6A, ALCAM, CD163, SLC2A9, FCGR2A, IGF2R, LAIR1, IL10RA, CPM, ADGRE2, FCGR3A, NRP1, and SCARB2, shows elevated expression in Microglia from both E280A and Sporadic AD samples compared to Control. These markers generally exhibit higher mean expression and fraction of positive cells in disease conditions. While there is overlap, some markers show particularly strong upregulation in E280A (e.g., MSR1, OLR1) or appear consistently high across both AD conditions. This suggests common microglial activation or dysfunction pathways shared between familial and sporadic forms of AD.
• Intra-Condition Variability: Within each condition, there is some variability in marker expression across individual samples, which is expected given the biological heterogeneity of human samples. However, the overall condition-specific patterns are robust.

Biological Interpretation

The distinct sets of surfaceome markers highlight significant shifts in microglial phenotype and function in Alzheimer's Disease (AD), distinguishing homeostatic Microglia from disease-associated states.

Markers Enriched in Control Microglia (Homeostatic/Surveillance Microglia)

These markers characterize Microglia in a non-diseased state, primarily involved in brain surveillance and maintaining homeostasis. Their downregulation in AD suggests a loss of these functions or a shift away from this state.

• CX3CR1: This chemokine receptor is a key marker of homeostatic Microglia, crucial for their interactions with neurons. It mediates responses to CX3CL1 (fractalkine) released by neurons, regulating microglial motility, synapse pruning, and anti-inflammatory functions. Reduced CX3CR1 signaling can lead to synaptic dysfunction and enhanced neurotoxicity in AD models.
  • Pathway: CX3CL1-CX3CR1 signaling axis.
  • Mechanism: Promotes microglial ramification, surveillance, and limits aberrant phagocytosis of synapses.
  • GeneCards: CX3CR1
• ITGAM (CD11b): As a subunit of the integrin complement receptor 3 (CR3/MAC-1), CD11b is broadly expressed on immune cells, including Microglia. It is involved in adhesion, phagocytosis (e.g., of cellular debris, opsonized particles), and inflammatory responses. Its presence in homeostatic Microglia suggests its role in basal clearance mechanisms.
  • Pathway: Integrin signaling, complement pathway.
  • Mechanism: Cell adhesion, phagocytosis, and modulation of inflammatory responses.
  • GeneCards: ITGAM
• MRC1 (CD206): The Mannose Receptor 1 is a C-type lectin involved in the phagocytosis of glycosylated ligands and pathogens. It is often associated with alternatively activated (M2-like) macrophages/Microglia, which are involved in tissue repair, immune regulation, and anti-inflammatory processes. Its higher expression in control suggests a basal anti-inflammatory or debris-clearance capacity.
  • Pathway: Phagocytosis, pattern recognition.
  • Mechanism: Clearance of cellular debris, pathogens, and dampening of inflammation.
  • GeneCards: MRC1

Markers Enriched in E280A and Sporadic Microglia (Disease-Associated Microglia)

These markers are indicative of a modified microglial state in AD, often linked to inflammatory responses, altered phagocytic activity, and disease pathology.

• MSR1 (CD204): Macrophage Scavenger Receptor 1 is involved in the uptake of modified lipoproteins and amyloid-beta (Aβ). Its upregulation in AD Microglia suggests an attempt to clear Aβ plaques, but this process may become dysfunctional over time, contributing to pathology.
  • Pathway: Scavenger receptor pathway, phagocytosis.
  • Mechanism: Binds and internalizes various modified self-components and pathogens, including Aβ.
  • GeneCards: MSR1
• OLR1 (LOX-1): Oxidized Low-Density Lipoprotein Receptor 1 is expressed on endothelial cells, macrophages, and Microglia. It mediates the uptake of oxidized LDL (oxLDL), which is implicated in inflammation and neurodegeneration. Upregulation suggests a response to oxidative stress and lipid dyshomeostasis in AD.
  • Pathway: Lipid metabolism, inflammatory signaling.
  • Mechanism: Receptor for oxLDL, contributing to inflammation and foam cell formation; in Microglia, it may contribute to the response to lipid pathology.
  • GeneCards: OLR1
• CD163: A scavenger receptor expressed by anti-inflammatory macrophages/Microglia (M2-like). It clears hemoglobin-haptoglobin complexes and has immunomodulatory functions. Its upregulation in AD Microglia might reflect an attempt to resolve inflammation or a specific adaptive response to neuronal damage and debris.
  • Pathway: Scavenger receptor pathway, iron homeostasis, anti-inflammatory signaling.
  • Mechanism: Binds hemoglobin-haptoglobin complexes, facilitates iron recycling, and dampens inflammation.
  • GeneCards: CD163
• FCGR2A (CD32a) and FCGR3A (CD16a): These are Fc gamma receptors that bind to the Fc portion of immunoglobulins. FCGR2A is an activating receptor, while FCGR3A is typically found on NK cells and macrophages. Their upregulation suggests increased immune complex clearance or antibody-mediated effector functions in AD, potentially linked to altered IgG levels or autoantibodies.
  • Pathway: Fc-mediated immune responses.
  • Mechanism: Mediate phagocytosis, antibody-dependent cellular cytotoxicity, and release of inflammatory mediators.
  • GeneCards: FCGR2A
  • GeneCards: FCGR3A
• IL10RA: Interleukin-10 receptor subunit alpha is part of the receptor complex for IL-10, a potent anti-inflammatory cytokine. Upregulation of its receptor suggests Microglia are primed to respond to IL-10, potentially indicating a compensatory anti-inflammatory response to chronic neuroinflammation in AD.
  • Pathway: IL-10 signaling pathway.
  • Mechanism: Mediates IL-10's immunosuppressive and anti-inflammatory effects, crucial for regulating immune responses in the brain.
  • GeneCards: IL10RA
• NRP1 (Neuropilin 1): A co-receptor for various ligands, including semaphorins and VEGF, involved in axonal guidance, angiogenesis, and immune regulation. In Microglia, NRP1 can modulate their activation and migration, potentially influencing neuroinflammation and neurovascular unit integrity in AD.
  • Pathway: Semaphorin signaling, VEGF signaling.
  • Mechanism: Modulates cellular migration, adhesion, and immune responses.
  • GeneCards: NRP1

Clinical or Translational Implications

The identified condition-specific surfaceome markers in Microglia offer promising avenues for biomarker development and therapeutic intervention in Alzheimer's Disease.

1. Biomarker Potential:
   • Diagnostic/Prognostic Markers: The differential expression of surface markers like CX3CR1 (downregulated in AD) and MSR1, OLR1, CD163, FCGR2A/3A (upregulated in AD) could serve as highly specific indicators of microglial activation states in AD. These could potentially be assessed in brain imaging (e.g., PET ligands targeting specific receptors) or, if found to be shed, in biofluids.
   • Monitoring Disease Progression: Changes in the expression of these markers over time could track disease progression or response to treatment.
2. Therapeutic Targets:

Modulating Microglial State:

• CX3CR1 agonists: Strategies to enhance CX3CR1 signaling in AD could potentially restore homeostatic microglial functions, reduce neuroinflammation, and improve synaptic health. This could involve direct agonists or therapies that promote CX3CL1 production.
• Targeting Scavenger Receptors (MSR1, OLR1, CD163): While involved in Aβ clearance, excessive or dysfunctional activation of these receptors could contribute to chronic inflammation or impaired clearance. Modulating their activity could optimize microglial phagocytic capacity without inducing detrimental inflammation. For instance, enhancing MSR1-mediated Aβ clearance without activating pro-inflammatory pathways could be beneficial.
• Fc Receptor Modulation: Given the upregulation of FCGR2A/3A, therapies targeting these receptors could modulate antibody-mediated microglial responses. This could be particularly relevant for immunotherapies that involve antibody administration (e.g., anti-Aβ antibodies) to ensure optimal and safe immune cell engagement.

• Anti-inflammatory Strategies: The upregulation of IL10RA in AD Microglia suggests that attempts to boost anti-inflammatory signaling (e.g., through IL-10 mimetics or enhancers of the IL-10 pathway) might be a viable approach to dampen neuroinflammation.
• Targeting Lipid Metabolism and Oxidative Stress: OLR1's upregulation points to the importance of lipid dyshomeostasis and oxidative stress in AD pathology. Therapeutic interventions targeting lipid metabolism or reducing oxidative stress could indirectly modulate microglial activation via OLR1.
• Neuropilin-1 (NRP1) Inhibition: Given NRP1's role in angiogenesis, axonal guidance, and immune responses, its upregulation in AD Microglia suggests it might contribute to pathological microglial migration or interactions. Modulating NRP1 activity could impact neuroinflammation and neurovascular integrity.
• MS4A6A: As a genetic risk factor for AD, MS4A6A represents a target where understanding its precise role in microglial function and lipid metabolism could lead to novel therapeutic strategies.

3. Experimental Validation:
   • Further studies using *in vitro* microglia models, AD animal models, and human brain tissues are needed to validate the functional consequences of altering the expression or activity of these surface markers.
   • Single-cell spatial transcriptomics could reveal the precise micro-environmental cues that drive these microglial phenotypic shifts *in situ*.
   • These surface markers are excellent candidates for flow cytometry or immunohistochemistry to characterize microglial states in AD brain samples.

10. Astrocyte Surfaceome Marker Expression Across Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers specifically expressed by Astrocytes across different conditions: Control, E280A (familial Alzheimer's Disease), and Sporadic (sporadic Alzheimer's Disease). The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for each sample within these conditions. The goal is to highlight condition-specific astrocyte surfaceome profiles that may shed light on disease mechanisms and potential therapeutic targets in Alzheimer's Disease. Markers were selected based on differential expression criteria (nz_pct_score and nz_pct FC) comparing each condition against a reference or "other" groups.

Visual Summary

The dot plot effectively delineates distinct patterns of astrocyte surfaceome marker expression across the Control, E280A, and Sporadic conditions.

• Condition-specific Clustering: Markers tend to cluster within their respective conditions, indicated by the red boxes highlighting markers enriched in Control, E280A, and Sporadic samples. This suggests unique astrocyte states or responses depending on the disease etiology (familial vs. sporadic AD) compared to healthy controls.
• Control-enriched Markers: A clear group of markers (e.g., GRIA2, GRM3, LINGO1, SEMA4D, SPP1) shows high expression and prevalence in Control astrocyte samples, with substantially lower or absent expression in E280A and Sporadic samples. These likely represent markers of healthy or baseline astrocyte function.
• E280A-enriched Markers: A distinct set of markers (e.g., PTCHD1, DDR1, DPP6, CD44, ABCC9, PAM, AQP1, OSMR, TMEM106B) exhibits elevated expression in E280A samples compared to Control and, to some extent, Sporadic samples. Some of these markers, like CD44 and PTCHD1, show shared upregulation in Sporadic samples, hinting at common pathological processes.
• Sporadic-enriched Markers: While some markers overlap with E280A (e.g., PTCHD1, CD44), a subset appears more pronounced in Sporadic samples (e.g., GRIK4, EVA1C, CRB2, CDH23). This indicates both shared and distinct astrocyte activation states between familial and sporadic forms of AD.
• Expression and Prevalence: For enriched markers, darker red colors (higher mean expression) and larger dot sizes (higher fraction of expressing cells) are consistently observed within their respective conditions, validating their specificity.

Biological Interpretation

Astrocytes are crucial for brain homeostasis, synaptic support, and immune response. In Alzheimer's Disease (AD), astrocytes undergo reactive astrogliosis, a complex remodeling process with both beneficial and detrimental aspects. The differential expression of surfaceome markers in this plot provides insights into these condition-specific astrocyte responses.

Markers Enriched in Control Astrocytes

• GRIA2 and GRM3 (Glutamate Receptor, Ionotropic, AMPA 2; Glutamate Receptor, Metabotropic 3): Astrocytes play a key role in glutamate homeostasis, regulating synaptic glutamate levels and expressing various glutamate receptors. High expression of GRIA2 (an AMPA receptor subunit) and GRM3 (a metabotropic glutamate receptor) in control astrocytes likely reflects their normal involvement in sensing neuronal activity and modulating synaptic transmission, as well as maintaining ion balance in the healthy brain [Source: GeneCards GRIA2, GRM3]. Their reduced presence in AD conditions might indicate a dysregulation of glutamate sensing or processing by astrocytes in disease.
• LINGO1 (Leucine Rich Repeat And Ig Domain Containing Nogo Receptor Interacting Protein 1): LINGO1 is known to inhibit neurite outgrowth and oligodendrocyte differentiation, acting as a negative regulator of neuronal plasticity and myelination [Source: PubMed Search: LINGO1 neurodegeneration]. Its higher expression in control astrocytes might reflect a mature, stable brain microenvironment, and its downregulation in AD could imply an attempt at plasticity or repair, or a disruption of normal inhibitory signaling.

Markers Enriched in E280A Astrocytes

The E280A mutation in the *PSEN1* gene is a cause of early-onset familial AD, characterized by aggressive amyloid pathology. Markers enriched here likely reflect specific astrocyte responses to this aggressive pathology.

• CD44 (CD44 Molecule (Indian Blood Group)): CD44 is a widely recognized cell surface glycoprotein that acts as a receptor for hyaluronan and other extracellular matrix components. It is a well-established marker of reactive astrocytes in various neurological disorders, including AD [Source: PubMed Search: CD44 reactive astrocytes Alzheimer's]. Upregulation of CD44 is associated with astrocyte activation, migration, proliferation, and inflammatory responses. In AD, CD44-mediated signaling can influence plaque formation and neuroinflammation.
• TMEM106B (Transmembrane Protein 106B): TMEM106B is a lysosomal protein strongly implicated in lysosomal function and neurodegeneration, particularly frontotemporal lobar degeneration (FTLD) and AD. Genetic variants in *TMEM106B* are associated with increased risk for FTLD and can influence AD pathology [Source: GeneCards TMEM106B]. Its upregulation in E280A astrocytes suggests altered lysosomal biology, which is a known feature of AD pathogenesis, impacting waste clearance and processing of amyloid-beta.
• DDR1 (Discoidin Domain Receptor Tyrosine Kinase 1): DDR1 is a receptor tyrosine kinase activated by collagen. It plays a role in cell adhesion, migration, proliferation, and extracellular matrix remodeling. In the context of AD, DDR1 can mediate inflammatory responses and contribute to neurovascular dysfunction and scar formation [Source: PubMed Search: DDR1 Alzheimer's astrocytes]. Its increased expression points to astrocytes actively remodeling the ECM, possibly in response to amyloid deposition and neuroinflammation.
• OSMR (Oncostatin M Receptor): OSMR is a receptor for oncostatin M, a cytokine of the IL-6 family. Activation of OSMR signaling in astrocytes can induce inflammatory responses, astrocyte proliferation, and contribute to gliosis [Source: PubMed Search: OSMR astrocytes neuroinflammation]. Elevated OSMR indicates a heightened inflammatory state in astrocytes in familial AD, potentially exacerbating neurodegeneration.

Markers Enriched in Sporadic Astrocytes

Sporadic AD is the most common form, with complex etiology. Markers enriched here may highlight generalized or specific astrocyte responses to a broader range of pathological triggers.

• CD44 (CD44 Molecule (Indian Blood Group)): As observed in E280A, CD44 is also highly expressed in sporadic AD astrocytes. This reinforces CD44 as a general marker of reactive astrogliosis across different AD etiologies, suggesting a common cellular response to amyloid-beta accumulation and neuroinflammation [Source: PubMed Search: CD44 reactive astrocytes Alzheimer's].
• PTCHD1 (Patched Homolog 1): PTCHD1 is a component of the Hedgehog signaling pathway. While primarily known for its role in development, Hedgehog signaling can be reactivated in adult tissues in response to injury and disease, influencing cell proliferation, differentiation, and tissue repair [Source: GeneCards PTCHD1]. Its upregulation in both E280A and Sporadic AD astrocytes suggests an attempt at cellular repair or a dysregulation of developmental pathways in disease.
• GRIK4 (Glutamate Receptor, Ionotropic, Kainate 4): GRIK4, a kainate receptor subunit, mediates excitatory neurotransmission. While primarily neuronal, its expression on astrocytes can imply a role in sensing excitotoxic signals or modulating synaptic function [Source: GeneCards GRIK4]. Elevated GRIK4 could contribute to astrocyte dysfunction under conditions of excitotoxicity, which is a feature of AD pathophysiology.
• EVA1C (EVA1 Family Member C): EVA1C has been implicated in various cellular processes including apoptosis, autophagy, and inflammation. Its role in the brain, particularly in astrocytes, is less characterized but its association with cell death and inflammatory pathways suggests a contribution to the neurodegenerative processes in sporadic AD [Source: GeneCards EVA1C].

Clinical or Translational Implications

The identification of condition-specific astrocyte surfaceome markers holds significant clinical and translational implications for Alzheimer's Disease:

• Biomarker Discovery: Surfaceome markers are ideal candidates for *in vivo* imaging or fluid-based biomarker detection because they are accessible on the cell surface. Markers like CD44 could serve as general indicators of astrocyte reactivity in AD, regardless of etiology. Specific upregulation of TMEM106B in familial AD astrocytes could be a more specific marker for this subtype or lysosomal dysfunction.

Therapeutic Target Identification:

• CD44: Given its role in astrocyte activation and inflammation, targeting CD44 or its downstream signaling could potentially modulate astrogliosis and neuroinflammation in AD. Inhibiting CD44 activity might reduce detrimental aspects of reactive astrocytes, such as scar formation and inflammatory cytokine release [Source: PubMed Search: CD44 inhibition Alzheimer's].
• TMEM106B: Modulating TMEM106B expression or function could be a therapeutic strategy to restore lysosomal integrity and function in AD. Given its direct link to AD pathology, understanding its regulation in astrocytes could lead to novel small molecule or genetic interventions [Source: PubMed Search: TMEM106B therapeutics neurodegeneration].
• OSMR: As a receptor for an inflammatory cytokine, OSMR presents a potential target for anti-inflammatory therapies. Blocking OSMR signaling in reactive astrocytes might dampen the neuroinflammatory cascade in AD, reducing neuronal damage [Source: PubMed Search: Oncostatin M receptor antagonist neuroinflammation].
• Glutamatergic Receptors (GRIA2, GRM3, GRIK4): Altered expression of these receptors suggests dysregulated glutamate signaling in AD astrocytes. Interventions aimed at restoring proper glutamate homeostasis or modulating astrocytic glutamate receptor activity could improve synaptic function and reduce excitotoxicity.

• Understanding Disease Heterogeneity: The distinct marker profiles between E280A and Sporadic AD astrocytes underscore the heterogeneity of the disease. Tailored therapeutic approaches might be necessary for different AD subtypes, and these markers could help stratify patients or monitor treatment efficacy. For example, specific modulation of Hedgehog pathway components (PTCHD1, BOC) might be more relevant in certain AD contexts.
• Experimental Validation: These identified surfaceome markers provide excellent candidates for further experimental validation using techniques like immunohistochemistry, flow cytometry, or *in situ* hybridization to confirm their expression patterns and functional roles in AD brain tissue. This could lead to the development of specific antibodies or imaging probes for AD diagnosis and monitoring.

11. Gene Ontology (GSA) Analysis of Neuronal Pathways in Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the enrichment of Gene Ontology (GO) terms within up-regulated differentially expressed genes (DEGs) in 'Neuron' cells across different Alzheimer's Disease (AD) conditions (E280A and Sporadic) compared to a Control group, as well as a comparison of Control neurons against all other AD conditions combined. The primary goal is to identify distinct or shared biological pathways dysregulated in neurons in familial (E280A) and sporadic AD, relative to healthy controls. The results are presented as bar plots showing the top enriched GO terms based on statistical significance (-log(p-val) and -log(q-val)).

Visual Summary

The analysis provides three bar plots illustrating enriched GO terms for up-regulated genes in neuronal cells under different comparison contexts:

1. GSA for Neuron: Control_vs_others: This plot displays GO terms enriched in genes that are significantly up-regulated in Control neurons when compared to all other AD conditions (E280A and Sporadic) combined. The most prominent terms exhibit very high significance, suggesting robust activation of certain pathways in healthy neurons relative to AD. Top enriched terms include "Pathways of neurodegeneration," "Parkinson disease," "Prion disease," "Huntington disease," "Amyotrophic lateral sclerosis," "Alzheimer disease," "Ribosome," and "Oxidative phosphorylation." The high -log(p-val) and -log(q-val) indicate a strong statistical signal.
2. GSA for Neuron: E280A_vs_Control: This plot highlights GO terms enriched in genes that are significantly up-regulated in E280A (familial AD) neurons compared to Control neurons. The overall significance levels (-log(p-val) and -log(q-val)) are lower than in the "Control_vs_others" comparison but still demonstrate clear enrichment. Key enriched terms include "Ubiquitin mediated proteolysis," "Axon guidance," "Endocytosis," "RNA degradation," "Protein processing in endoplasmic reticulum," "MAPK signaling pathway," "Autophagy," "ErbB signaling pathway," and "Glutamatergic synapse."
3. GSA for Neuron: Sporadic_vs_Control: This plot shows GO terms enriched in genes that are significantly up-regulated in Sporadic AD neurons compared to Control neurons. Similar to the E280A comparison, significance levels are moderate. Notable enriched terms include "Axon guidance," "Endocytosis," "Ubiquitin mediated proteolysis," "Phosphatidylinositol signaling system," "Inositol phosphate metabolism," "MAPK signaling pathway," "Herpes simplex virus 1 infection," "Autophagy," "Lysine degradation," and "Insulin resistance."

Biological Interpretation

The Gene Ontology analysis reveals critical insights into neuronal dysfunction in Alzheimer's Disease, distinguishing between healthy, familial AD (E280A mutation), and sporadic AD.

• Control Neurons Exhibit Robust Homeostasis and Resilience: The "Control_vs_others" plot, showing terms up-regulated in Control neurons relative to AD, strongly suggests that healthy neurons maintain high activity in pathways crucial for general cellular health and resilience against neurodegeneration. The enrichment of terms like "Pathways of neurodegeneration," "Alzheimer disease," "Parkinson disease," etc., implies that genes associated with *maintaining normal neuronal function and combating these disease processes* are more active in healthy controls. Similarly, the high enrichment of "Ribosome" and "Oxidative phosphorylation" indicates robust protein synthesis and energy metabolism, which are fundamental for neuronal function and often impaired in neurodegenerative conditions. PubMed search: Oxidative phosphorylation Alzheimer's disease neurons
• Shared Pathological Mechanisms in Familial (E280A) and Sporadic AD Neurons: Both E280A and Sporadic AD neurons show up-regulation in several common pathways when compared to Control:
  • Protein Misfolding and Degradation: Terms like "Ubiquitin mediated proteolysis," "Protein processing in endoplasmic reticulum" (indicative of ER stress), and "Autophagy" are highly enriched. This points to a heightened cellular response to accumulating misfolded or damaged proteins, a hallmark of AD pathology, as neurons attempt to clear toxic aggregates. GeneCards: APP
  • Synaptic and Neuronal Connectivity Changes: "Axon guidance," "Endocytosis," and "Glutamatergic synapse" (for E280A) suggest significant alterations in neuronal connectivity, synaptic function, and neurotransmission. Dysfunctional endocytosis is known to impact amyloid precursor protein (APP) processing and Aβ generation. PubMed search: Endocytosis Alzheimer's disease synaptic dysfunction
  • Cellular Stress Signaling: "MAPK signaling pathway" and "ErbB signaling pathway" (for E280A) highlight activation of general stress responses, which can be both protective and detrimental depending on their duration and context.

Distinctive Features of E280A and Sporadic AD Neurons

• E280A Specifics: "RNA degradation" is prominent in E280A, suggesting potential dysregulation of RNA metabolism, which can impact gene expression and protein synthesis. The specific mutation in E280A (PSEN1 E280A) is known to alter γ-secretase activity, affecting APP processing and Aβ production.
• Sporadic AD Specifics: "Phosphatidylinositol signaling system," "Inositol phosphate metabolism," and "Insulin resistance" are more pronounced in sporadic AD. This emphasizes the role of lipid metabolism dysfunction and impaired insulin signaling within neurons, often referred to as "type 3 diabetes" in the brain, contributing significantly to sporadic AD pathogenesis. PubMed search: Insulin resistance brain Alzheimer's disease
• Viral Hypothesis: The enrichment of "Herpes simplex virus 1 infection" in sporadic AD is particularly noteworthy, lending support to theories that viral infections might contribute to or exacerbate AD pathology. PubMed search: Herpes simplex virus Alzheimer's disease

Clinical or Translational Implications

The findings offer several potential clinical and translational implications for Alzheimer's Disease:

• Biomarker Discovery: The distinct sets of up-regulated pathways in E280A and sporadic AD neurons, especially compared to control, could yield novel gene expression biomarkers for early disease detection, differentiation between AD subtypes, or monitoring disease progression, particularly from neuronal-derived exosomes or CSF.
• Therapeutic Targets: The identified dysregulated pathways, such as protein quality control (ubiquitin proteolysis, ER stress, autophagy), synaptic remodeling (axon guidance, endocytosis), and metabolic dysfunction (insulin resistance, lipid metabolism), represent potential targets for therapeutic intervention. Modulating these pathways could restore neuronal homeostasis or mitigate neurodegeneration.
  • For example, drugs targeting specific components of the ubiquitin-proteasome system or autophagy could help manage protein aggregation.
  • Strategies to improve neuronal insulin sensitivity might be beneficial for sporadic AD.
• Disease Subtype Specificity: The observed differences between E280A and sporadic AD suggest that a "one-size-fits-all" treatment approach might be suboptimal. Understanding these pathway distinctions could lead to the development of more personalized and effective therapeutic strategies tailored to the specific mechanisms driving familial vs. sporadic forms of the disease.
• Infectious Etiology Re-evaluation: The strong signal for "Herpes simplex virus 1 infection" in sporadic AD warrants further investigation into the role of viral pathogens in AD development and progression. Antiviral therapies could be explored as a potential strategy for a subset of AD patients.

12. Gene Set Enrichment Analysis of Alzheimer's Disease Conditions Across Brain Cell Types

[Analysis Visualization Results]...

Analysis Overview

This report presents the results of a Gene Set Enrichment Analysis (GSEA) performed on single-cell RNA-seq data from various brain cell types (Astrocytes, Endothelial cells, Microglia, Neurons, Oligodendrocytes, and Oligodendrocyte progenitor cells). The analysis compares gene expression profiles in Alzheimer's disease (AD) conditions—specifically E280A (a familial AD mutation) and Sporadic AD—against a healthy Control group. Additionally, comparisons of the Control group against the combined disease conditions ("Control_vs_others") are included. The dot plot visualizes the Normalized Enrichment Score (NES) using a color gradient (red for positive NES, indicating upregulation; blue for negative NES, indicating downregulation) and the statistical significance (-log(P)) via dot size (larger dots representing higher significance). The goal is to identify pathways and biological processes that are dysregulated in AD across different brain cell populations.

Visual Summary

The GSEA dot plot provides a detailed landscape of pathway activity changes within the brain in Alzheimer's disease:

• Extensive Pathway Dysregulation: The plot reveals widespread and statistically significant alterations in numerous biological pathways across nearly all interrogated cell types in both E280A and Sporadic AD conditions when compared to controls. This indicates profound molecular reprogramming associated with the disease.
• Cell Type-Specific Responses: While many pathways show broad involvement, there's a clear emphasis on Microglia, Neurons, Oligodendrocytes, and Oligodendrocyte progenitor cells, which exhibit the most numerous and intense pathway enrichments or repressions. Astrocytes also show significant changes, whereas Endothelial cells exhibit a more focused set of affected pathways.
• Consistent Disease Signatures: For most significantly perturbed pathways, the E280A and Sporadic AD conditions demonstrate largely consistent directions and magnitudes of change relative to the Control group. This suggests common underlying pathogenic mechanisms between familial and sporadic forms of AD.
• Prominent Upregulated Pathways: Pathways associated with neuroinflammation, immune responses, cellular stress, and protein processing are consistently upregulated. Key examples include "NF-kappa B signaling pathway", "JAK-STAT signaling pathway", "Inflammatory mediator regulation of TRP channels", "Protein processing in endoplasmic reticulum", "Apoptosis", "Autophagy", and "Cellular senescence". Intriguingly, several infection-related pathways (e.g., "Toxoplasmosis", "Shigellosis", "Bacterial invasion of epithelial cells", "Human cytomegalovirus infection") are also highly enriched, potentially reflecting a generalized innate immune activation or stress response.
• Prominent Downregulated Pathways: Conversely, pathways related to metabolic regulation and specific neuronal functions show consistent downregulation. Notable examples include "ABC transporters", "Adipocytokine signaling pathway", "Glucagon signaling pathway", "Cholinergic synapse", "PPAR signaling pathway", and "Thyroid hormone synthesis".
• High Significance: The large size of many dots throughout the plot underscores the high statistical significance of the observed pathway enrichments and repressions, with -log(P) values frequently exceeding 12, 18, or even 24.

Biological Interpretation

The observed GSEA results provide strong biological insights into the multifaceted pathology of Alzheimer's disease:

• Pervasive Neuroinflammation: The consistent upregulation of key inflammatory signaling pathways like "NF-kappa B signaling pathway" [1] and "JAK-STAT signaling pathway" across Microglia, Neurons, Oligodendrocytes, and Oligodendrocyte progenitor cells highlights a central role for neuroinflammation in AD. Microglia, as innate immune cells, are expected to be activated, but the involvement of neurons and other glial cells signifies a broader inflammatory environment. The enrichment of infection-related pathways might suggest an exaggerated innate immune response, which can contribute to chronic inflammation and neurodegeneration.
• Cellular Stress and Proteinopathy: The significant upregulation of "Protein processing in endoplasmic reticulum" across multiple cell types is highly relevant to AD, as the accumulation of misfolded amyloid-beta and tau proteins is a hallmark of the disease, leading to ER stress and the unfolded protein response [2]. Furthermore, the activation of "Apoptosis" pathways indicates increased programmed cell death, while "Autophagy" upregulation suggests cellular attempts to clear damaged components, processes that often become dysfunctional in AD. "Cellular senescence" also points to an accumulation of senescent cells contributing to chronic inflammation and tissue damage.
• Metabolic and Lipid Dysregulation: The downregulation of "ABC transporters", particularly in Microglia and Neurons, is noteworthy as these transporters are crucial for the efflux of amyloid-beta and other waste products from the brain [3]. Impaired ABC transporter function can contribute to amyloid accumulation. The repression of "Adipocytokine signaling pathway" and "PPAR signaling pathway" suggests dysregulation of lipid metabolism and energy homeostasis, which are increasingly implicated in AD pathogenesis.
• Neuronal and Synaptic Dysfunction: The prominent downregulation of "Cholinergic synapse" in neurons directly supports the well-established cholinergic deficit hypothesis in AD, which is targeted by current symptomatic treatments. Dysregulation of "Glutamatergic synapse" activity, coupled with changes in "Neurotrophin signaling pathway", further points to broad synaptic and neuronal health impairments.
• Oligodendrocyte and Myelin Pathology: The widespread pathway alterations in Oligodendrocytes and Oligodendrocyte progenitor cells (e.g., in inflammatory and stress response pathways) underscore the involvement of white matter degeneration and myelination defects in AD, contributing to compromised neural circuit function.
• Cerebrovascular Compromise: Endothelial cells show dysregulation in "ECM-receptor interaction" and "Fluid shear stress and atherosclerosis", suggesting potential impairments in blood-brain barrier integrity, vascular function, and cerebral blood flow, which are critical components of AD pathology.

Clinical or Translational Implications

These GSEA findings have important implications for understanding and potentially treating Alzheimer's disease:

• Targeting Neuroinflammation: The consistent activation of NF-kappa B and JAK-STAT signaling pathways across multiple brain cell types highlights these as promising therapeutic targets for mitigating neuroinflammation and its detrimental effects in AD.
• Addressing Protein Misfolding and Cellular Stress: Pathways related to ER stress, apoptosis, and autophagy represent potential intervention points to prevent protein aggregation, reduce neuronal loss, and enhance cellular clearance mechanisms.
• Metabolic and Lipid Modulators: The observed dysregulation of lipid metabolism and ABC transporters suggests that strategies aimed at improving lipid homeostasis or enhancing transporter function could be beneficial in AD.
• Refining Cholinergic Therapies: The clear evidence of "Cholinergic synapse" downregulation in neurons reinforces the rationale for developing more effective or targeted therapies that enhance cholinergic neurotransmission.
• Multifaceted Disease Approach: The pervasive and interconnected pathway dysregulations across diverse brain cell types underscore that AD is a complex, multi-cellular disease. Effective therapeutic strategies will likely need to adopt a multi-target approach, addressing neuroinflammation, proteinopathy, metabolic dysfunction, and neuronal integrity simultaneously.

---

References:

[1] NF-kappa B signaling pathway: https://www.genecards.org/Search/Keyword?query=NF-kappa%20B%20signaling%20pathway

[2] Protein processing in endoplasmic reticulum in neurodegenerative diseases: https://pubmed.ncbi.nlm.nih.gov/?term=protein+processing+endoplasmic+reticulum+neurodegeneration

[3] ABC transporters and Alzheimer's disease: https://pubmed.ncbi.nlm.nih.gov/?term=ABC+transporters+Alzheimer%27s+disease

13. Discussion

This comprehensive single-cell analysis of human brain tissue elucidates the complex cellular and molecular landscape of Alzheimer's Disease (AD), distinguishing between familial (E280A mutation) and sporadic forms, and contrasting them with healthy controls. A foundational finding is the profound shift in cell population dynamics: a hallmark neuronal loss coupled with reactive gliosis, evidenced by increased astrocyte and microglia proportions, particularly prominent in sporadic AD samples. Microglial populations undergo significant phenotypic changes, moving from a homeostatic M0 state towards M2-like phenotypes (M2a, M2c increases in both AD forms), with a notable, statistically significant increase in M2b microglia specifically in sporadic AD. This suggests distinct, potentially maladaptive, immune responses contributing to the pathology of different AD subtypes.

Intercellular communication analysis reveals widespread dysregulation impacting synaptic integrity, lipid metabolism, and neuroinflammation across both familial and sporadic AD. Common alterations include intensified glutamatergic signaling, altered synaptic adhesion (NRXN-NLGN pairs), and perturbed cholesterol transport (Cholesterol_byLRP_and_APOE), along with persistent SPP1-integrin mediated neuroinflammation. However, critical distinctions emerge: E280A AD shows a pronounced role for GABA-GABBR1 interactions and altered APP-SORL1 processing, suggesting specific disruptions in inhibitory neurotransmission and amyloid precursor protein trafficking. In contrast, sporadic AD is characterized by highly active Glutamate-GRM1 signaling and impaired astrocytic glutamate clearance (SLC1A3), indicating profound excitotoxicity. Additionally, APP-CD74 interactions point to specific inflammatory pathways involving APP in sporadic AD. These findings highlight shared overarching pathological processes but also distinct molecular drivers influencing disease progression in familial and sporadic AD.

Cell-specific marker expression and Gene Ontology/GSEA analyses further dissect these disease mechanisms. Control neurons exhibit robust expression of genes involved in cellular homeostasis, protein synthesis, and oxidative phosphorylation, which appear diminished or dysregulated in AD. In AD neurons, there's a heightened cellular response to protein misfolding (ubiquitin-mediated proteolysis, ER stress, autophagy), profound synaptic and neuronal connectivity changes (axon guidance, endocytosis), and activation of general stress pathways (MAPK, ErbB signaling). Distinctively, sporadic AD neurons show prominent dysregulation of lipid metabolism and insulin signaling pathways ('type 3 diabetes' in the brain), alongside a striking enrichment for Herpes simplex virus 1 infection pathways. Familial AD neurons, meanwhile, display unique RNA degradation signatures. Microglia shift from homeostatic markers (CX3CR1, ITGAM, MRC1) to disease-associated phenotypes (MSR1, OLR1, CD163, FCGR2A/3A, IL10RA, NRP1), indicating altered phagocytosis, lipid responses, and immune complex handling. Reactive astrocytes across AD conditions upregulate CD44, with E280A astrocytes uniquely enriching TMEM106B (lysosomal dysfunction) and OSMR (inflammatory signaling), while sporadic AD astrocytes show GRIK4 (excitotoxicity sensing). Across all cell types, GSEA reveals pervasive neuroinflammation (NF-kappa B, JAK-STAT), cellular stress (apoptosis, cellular senescence), and metabolic dysregulation (ABC transporters, PPAR signaling). The clear downregulation of 'Cholinergic synapse' pathways in neurons also reinforces a well-established AD deficit.

In conclusion, while familial and sporadic AD converge on common downstream pathogenic mechanisms such as neuroinflammation, proteinopathy, and synaptic dysfunction, our high-resolution analysis reveals crucial subtype-specific differences at the cellular interaction, marker, and pathway levels. These distinctions underscore the heterogeneous nature of AD and suggest that future therapeutic strategies may need to adopt personalized approaches, targeting specific cellular dysregulations and intercellular communication networks relevant to individual AD subtypes or patient profiles. The unexpected strong signal for infection-related pathways, particularly Herpes simplex, warrants further investigation into potential infectious etiologies or generalized immune activation in AD pathogenesis.

Hypotheses:

1. Sporadic Alzheimer's Disease is characterized by a distinct microglial polarization signature, including an increase in M2b microglia, reflecting a unique, potentially maladaptive, immune response compared to familial AD and controls.
2. The profound glutamatergic excitotoxicity and impaired astrocytic glutamate clearance (mediated by SLC1A3 and GRM1 dysregulation) in sporadic AD contributes significantly more to neuronal damage than in familial AD, where GABAergic alterations (e.g., GABA-GABBR1) might be a dominant driver.
3. Distinct dysregulations in APP processing and trafficking pathways, specifically altered APP-SORL1 interactions in familial AD and APP-CD74 inflammatory interactions in sporadic AD, contribute to differential amyloid pathology and neuroinflammation in these AD subtypes.
4. Neurons in sporadic Alzheimer's Disease exhibit specific dysregulation of lipid metabolism and insulin signaling pathways that are critical and unique contributors to neurodegeneration, beyond general protein quality control issues.
5. The enrichment of viral infection-related pathways, particularly Herpes simplex virus 1, in sporadic AD neurons suggests a potential role for infectious agents or a generalized pathogen-response in the etiology or progression of this AD subtype.

Potential therapeutic targets:

1. Astrocyte CD44 / OSMR Signaling: Upregulation of CD44 marks reactive astrogliosis across AD, while OSMR upregulation in familial AD indicates heightened inflammatory signaling in astrocytes. Modulating these could dampen detrimental astrocytic inflammation and scar formation, which contribute to neurodegeneration. Evidence: Section 10 notes 'CD44 is a well-established marker of reactive astrocytes' and 'OSMR indicates a heightened inflammatory state' in AD astrocytes. Section 3 highlights 'increased proportions of Astrocytes... are indicative of reactive gliosis and neuroinflammation'. GSEA (Section 12) shows upregulation of JAK-STAT and NF-kappa B signaling pathways, which OSMR signaling can influence. Validation: Inhibiting CD44 or OSMR signaling using specific antibodies or small molecule inhibitors in AD animal models or human iPSC-derived astrocyte co-cultures, followed by assessment of inflammatory markers, amyloid burden, and neuronal survival.
2. Microglial MSR1 / OLR1 / Fc-Receptor Axis: Scavenger receptors MSR1 and OLR1, and Fc gamma receptors (FCGR2A, FCGR3A) are upregulated in AD microglia, indicating altered phagocytic activity, response to oxidative stress/lipid dyshomeostasis, and immune complex clearance. Optimizing their function could enhance beneficial amyloid clearance and dampen chronic inflammation without inducing detrimental effects. Evidence: Section 9 states: 'MSR1... involved in the uptake of modified lipoproteins and amyloid-beta (Aβ). Its upregulation in AD Microglia suggests an attempt to clear Aβ plaques...' and 'OLR1... upregulation suggests a response to oxidative stress and lipid dyshomeostasis.' Also, 'FCGR2A/3A... upregulation suggests increased immune complex clearance or antibody-mediated effector functions' in AD microglia. Validation: Employing gene editing (CRISPR) or pharmacological modulators to fine-tune MSR1, OLR1, or FcR activity in microglial cell lines or AD mouse models. Measure Aβ phagocytosis, inflammatory cytokine release, and plaque burden reduction.
3. Neuronal Glutamatergic & GABAergic Balance: Sporadic AD shows dysregulated Glutamate-GRM1 interactions, indicating excitotoxicity, a major contributor to neuronal damage. Familial AD shows prominent GABA-GABBR1 interactions, suggesting altered inhibitory tone. Restoring the balance of excitatory/inhibitory neurotransmission is crucial for preventing neuronal loss and improving cognitive function. Evidence: Section 7 details: 'Glutamate_byGLS2_and_SLC1A3_GRM1 -- Neuron | Astrocyte ... Upregulated glutamatergic signaling and impaired astrocytic glutamate clearance are hallmarks of excitotoxicity in AD...' and 'GABA_byGAD2_and_SLC6A1_GABBR1 -- Neuron | Oligodendrocyte ... Dysregulation of GABAergic signaling is a prominent feature in AD'. Section 8 also notes GRM1's importance in control neurons. Validation: Using GRM1 antagonists or GABBR1 modulators in AD animal models to assess neuronal excitability, synaptic integrity, and cognitive function. In vitro assays with human iPSC-derived neurons can test direct effects on neurotransmission and neuronal viability.
4. Lysosomal Function via TMEM106B in Astrocytes: Upregulation of TMEM106B in familial AD astrocytes suggests altered lysosomal biology, which is critical for cellular waste clearance, including amyloid-beta processing and degradation. Modulating its function could restore lysosomal integrity and improve waste removal in disease. Evidence: Section 10 states: 'TMEM106B is a lysosomal protein strongly implicated in lysosomal function and neurodegeneration... Its upregulation in E280A astrocytes suggests altered lysosomal biology, which is a known feature of AD pathogenesis, impacting waste clearance and processing of amyloid-beta.' Validation: Investigate the effect of TMEM106B genetic knockdown or overexpression in astrocyte cell lines or organoids on lysosomal enzyme activity, autophagic flux, and Aβ degradation. Animal models with targeted modulation of astrocytic TMEM106B can further assess impacts on AD pathology.

Follow-up validation ideas:

1. Utilize flow cytometry or immunohistochemistry for specific surface markers (e.g., microglial: CX3CR1, MSR1, CD163; astrocyte: CD44, TMEM106B; neuronal: ADAM10, HTR1E, LRFN2) to validate cell type proportions and marker expression changes in human AD brain tissue sections or isolated primary cells.
2. Apply spatial transcriptomics or proteomics to precisely map the localization and cell-cell context of identified marker changes (e.g., APP-SORL1, Glutamate-GRM1) and cell-cell interaction patterns *in situ* within AD brain regions.
3. Conduct *in vitro* (e.g., iPSC-derived neuron/glial co-cultures) or *in vivo* (e.g., AD animal models) perturbation assays to functionally test the roles of key therapeutic targets (e.g., modulating ADAM10 activity, blocking OSMR, enhancing SLC1A3 function, or targeting GABBR1 or CD74) on amyloid pathology, neuroinflammation, and synaptic function.
4. Validate differential gene and protein expression for key markers and pathway components (e.g., related to ubiquitin proteolysis, ER stress, autophagy, lipid metabolism) across control, familial AD, and sporadic AD human brain samples using targeted qPCR or Western blot.
5. Investigate whether changes in the expression or shedding of cell-surface markers (e.g., CD44, MSR1, SORCS1) identified in specific cell types can be detected in CSF or blood plasma as potential diagnostic or prognostic biomarkers for AD subtypes.
6. Assess synaptic function and neuronal excitability in AD animal models or human iPSC-derived neurons/organoids following modulation of identified cell-cell interactions (e.g., glutamatergic or GABAergic signaling, neurexin-LRRTM pairs) using functional electrophysiology.

Limitations:

The current analysis is based on single-cell transcriptomics data, which provides correlative insights into gene expression and cell states rather than direct causal mechanisms. Inferred cell-cell interactions require experimental validation to confirm physical interactions and their functional consequences. The study relies on a fixed set of annotations and computational inference; while robust, these do not fully capture the continuous nature of cell states or all possible cellular heterogeneity. The relatively small sample size for each condition in some analyses, particularly for statistical comparisons between AD subtypes, warrants cautious interpretation of non-significant findings. Moreover, post-mortem brain tissue may present altered gene expression profiles compared to *in vivo* states due to tissue handling and degradation, and the precise stage of AD for each patient is not fully resolved in all comparisons. Lastly, the dataset reflects a specific brain region (not specified beyond 'Brain'), and findings may not generalize to all brain areas.

14. Query List

1. Show major cell type scores on UMAP and save the result.
2. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
3. Show and save a population bar plot of minor cell types.
4. Show and save a population bar plot of Microglia subsets.
5. Show and save box plots of Microglia subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
6. Show and save cell-cell interaction patterns. Select at most 80 cell-cell interactions per group.
7. Find cell-cell interactions involving major brain cells (such as Neuron, Oligodendrocyte, Astrocyte, and Microglia) that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms and, where relevant, its potential as a therapeutic target and related therapeutic agents.
8. Show marker expression for Neuron in a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the brain tissue and, where relevant, its potential as a therapeutic target for Alzheimer's Disease and related therapeutic agents.
9. Show marker expressions for Microglia in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the brain tissue and, where relevant, its potential as a therapeutic target for Alzheimer's Disease and related therapeutic agents.
10. Show marker expressions for Astrocyte in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the brain tissue and, where relevant, its potential as a therapeutic target for Alzheimer's Disease and related therapeutic agents.
11. Show Gene Ontology (GSA) analysis results for Neuron as a bar plot, and save the result.
12. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.